No Data
No Data
No Data
No Data
No Data
Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients With Preserved Ejection Fraction Heart Failure
Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on
BusinesswireMar 26 07:06 ET
AVROBIO's Strategic Ambiguity: A Commitment to Analysis With Uncertain Outcomes for Shareholders
TipRanksMar 16 02:01 ET
Avrobio (AVRO) Gets a Buy From Wells Fargo
TipRanksMar 15 06:47 ET
Shareholder Alert: Ademi LLP Investigates Whether AVROBIO, Inc. Has Obtained a Fair Price in Its Transaction With Tectonic
MILWAUKEE, Jan. 31, 2024 /PRNewswire/ -- Ademi LLP is investigating AVROBIO, Inc. (Nasdaq: AVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Tectonic.
PR NewswireJan 31 15:08 ET
Avrobio Buy Rating: Undervalued Merger Potential With Tectonic and Promising Fc-relaxin Asset for G2PH
TipRanksJan 31 05:50 ET
SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating AVROBIO, Inc. Merger
Wilmington, Delaware--(Newsfile Corp. - January 30, 2024) - Rigrodsky Law, P.A. is investigating AVROBIO, Inc. ("AVROBIO") (NASDAQ GS: AVRO) regarding possible breaches of fiduciary duties and other v
newsfileJan 30 16:21 ET
No Data
No Data
TrytosaveabitOP : Upon Completion of Merger, Combined Co Expected to Operate Under the Name Tectonic Therapeutic and Trade on Nasdaq Under Ticker Symbol